/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Valuation is the primary weakness (avg 45/100). Business quality is the relative bright spot.
Broad-market heuristics · Not a buy/sell signal
Valuation
Growth
Under 20x, reasonable relative to earnings
Negative FCF, no valuation support
Above 10% CAGR, strong compounder
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Shrinking >2%, active buybacks
Expanded 3+pp, strong improvement
Positive debt with no FCF to service it
Above 20%, exceptional capital efficiency
Indivior Pharmaceuticals (INDV) scores 59/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 7 metrics each scored 0 to 100, on 31.6% operating margins and 88.8% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
SourceQuality score computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 4 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Indivior Pharmaceuticals scores 59 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 31.6% operating margin and a 88.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from INDV's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Indivior Pharmaceuticals scores well and where it falls behind.
Indivior Pharmaceuticals earns about 88.8% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to INDV's margins and growth on this scorecard to judge durability.
Indivior Pharmaceuticals runs an operating margin of about 31.6% and a net margin of about 26.7%. Revenue has grown at roughly 11.2% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.